Introduction
Constitutive active mutations of type III receptor tyrosine kinases (RTK) such as FLT3, c-Kit and PDGFR are major causes of hematological malignancies (Reilly, 2002) . Among them, two types of constitutively active FLT3 mutations are frequently identified in leukemic blasts from the patients with acute myeloid leukemia (AML): one is internal tandem duplication (ITD) in the juxtamembrane domain and the other is missense mutations in the activation loop of the second tyrosine kinase domain (TKD) (Nakao et al., 1996; Yokota et al., 1997; Abu-Duhier et al., 2001; Yamamoto et al., 2001) . The ITD mutation is found in about B20% of AML patients, and associated with poor prognosis (Kiyoi et al., 1999; Abu-Duhier et al., 2000; Schnittger et al., 2002; Thiede et al., 2002) . The TKD mutation is detected in B7% of AML patients. Although the clinical relevance of TKD mutation has not been confirmed, some reports suggested the possible association with poor prognosis in younger patients with intermediate risk (Yamamoto et al., 2001; Thiede et al., 2002; Moreno et al., 2003) . TKD mutations are mainly caused by the missense mutations at Asp 835 (Asp at codon 835) of human FLT3 (Abu-Duhier et al., 2001; Yamamoto et al., 2001) . The Asp residue lies near the highly conserved Asp-Gly-Phe sequence of tyrosine kinase family, and occupies the equivalent position in other members of RTKs such as c-Kit and PDGFRa. TKD mutation of c-Kit has been reported to cluster at the corresponding Asp 816 residue, and are associated with mastocytosis or AML (Furitsu et al., 1993; Longley et al., 1996; Worobec et al., 1998; Care et al., 2003) . Furthermore, constitutively activating mutation at the Asp residue of kinase domain of PDGFRa has recently been identified in several cases of gastrointestinal stromal tumor (Heinrich et al., 2003; Hirota et al., 2003) .
The clinical significance of these TKD mutations is characterized by the resistance to the tyrosine kinase inhibitors. TKD mutations of c-Kit and PDGFRa showed resistance to imatinib, which can inhibit the wild-type (WT) and the juxtamembrane mutants of these kinases (Ma et al., 2002; Ueda et al., 2002; Heinrich et al., 2003; Hirota et al., 2003) . FLT3 TKD mutation also confers the resistance to some kind of tyrosine kinase inhibitors (Grundler et al., 2003) . Thus, TKD mutations confer resistance to tyrosine kinase inhibitors in different kinds of tyrosine kinases.
We have previously found that Phe substitution of Tyr 719 (Tyr719Phe) in c-Kit TKD-mutant, c-Kit Asp814Val , not only abolished the binding of PI3 kinase p85 subunit but also completely suppressed the receptor phosphorylation and ligand-independent proliferation (Hashimoto et al., 2003) . These results suggested that specific tyrosine residue may regulate the constitutive activation in the c-Kit TKD-mutant. Since not only the affected residue of FLT3 TKD-mutant and c-Kit TKD-mutant is conserved but also cytoplasmic tyrosine residues are almost conserved in both receptors, we examined whether specific tyrosine residues exist in FLT3 TKD-mutant, which regulate its constitutive activation.
Results
Effects of substitution of phenylalanine for tyrosine on the constitutive activation of mFLT3
Asp838Val
Murine FLT3 (mFLT3) has 22 cytoplasmic tyrosine residues, which correspond to respective tyrosine residues of human FLT3 (Figure 1 ). At first, we intended to estimate as to which cytoplasmic tyrosine residues are important for the activation of mFLT3 Asp838Val . Expression vectors pcDNA3 carrying 22 types of Tyr-Phe mutations of mFLT3
Asp838Val were transiently transfected to Plat-E cells. Without FLT3 ligand stimulation, the cell lysates were immunoprecipitated with anti-mFLT3 antibody and subjected to Western blotting with anti-phosphotyrosine antibody and anti-FLT3 antibody ( Figure 2 ). All Tyr-Phe mutants of mFLT3
Asp838Val as well as mFLT3
Asp838Val were composed of 140-kDa (immature) and 160-kDa (mature) form, and expressed at comparable level. mFLT3
Asp838Val showed distinct receptor phosphorylation without ligand stimulation. The substitution of phenylalanine for tyrosine at codon 796, 845, 892 or 922 (Tyr796Phe, Tyr845Phe, Tyr892Phe, Tyr922Phe, respectively) considerably impaired the phosphorylations of mFLT3
Asp838Val , both of mature and immature form, whereas other Tyr-Phe mutations did not.
For further study, we introduced Tyr796Phe, Tyr845Phe, Tyr892Phe and Tyr922Phe mutants of mFLT3
Asp838Val stably into Ba/F3 cells. All transfected cells sufficiently expressed mutated mFLT3 on cell surface ( Figure 3a ). We obtained cell lysates of these transfected cells and assessed the phosphorylation of these receptors by anti-phosphotyrosine antibody ( Figure 3b ). Tyr845Phe, Tyr892Phe and Tyr922Phe impaired the phosphorylation of mFLT3
Asp838Val in Ba/F3 cells, but Tyr796Phe did not. The extra phosphotyrosine bands in Tyr892Phe lanes were not mFLT3 bands judging from the molecular weight. We also analysed the activation of FLT3 by immunoblotting with anti-phospho-FLT3 monoclonal antibody (Figure 3c ). This monoclonal antibody detects FLT3 only when phosphorylated at Tyr 592 of mFLT3. Consistent with the results by anti-phophotyrosine antibody, Tyr845Phe, Tyr892Phe and Tyr922Phe impaired the autophosphorylation of Tyr 592 of mFLT3. Tyr892Phe and Tyr922Phe appeared to inhibit the phosphorylation more extensively than Tyr845Phe, as was indicated by the quantified phosphorylation rates. mFLT3
Asp838Val Figure 1 Structure of murine FLT3 (mFLT3) and list of cytoplasmic tyrosine residues. Substitution of valine (Val) for aspartic acid (Asp) at codon 838 (Asp838Val) results in constitutive activation of mFLT3. mFLT3 has 22 cytoplasmic tyrosine residues. Each tyrosine residue of mFLT3
Asp838Val at codon from 567 to 972 was changed to phenylalanine. Tyrosine residues of human FLT3, which correspond to those of mFLT3, are listed on the right panel Asp838Val were immunoprecipitated with antimFLT3 antibody from the lysates of transiently transfected Plat-E cells, and subjected to immunoblotting with anti-phosphotyrosine antibody (upper lanes) and anti-mFLT3 (lower lanes). Mobility of the mature (160 kDa) and immature (140 kDa) forms of mFLT3 is indicated by the arrows. All samples were cultured without FLT3 ligand. The results are shown as the representative of three independent experiments. 'Asp838Val' represents mFLT3 Asp838Val without Tyr-Phe mutation. 'Tyr567Phe' represents Tyr 567 -Phe mutant of mFLT3
Asp838Val , and so on
Critical tyrosine residues in FLT3 mutation J Ishiko et al showed constitutive activation and ligand stimulation did not augment the activation, which suggested the different activation mechanism from WT receptor. The lack of ligand-dependent increase of activation in other mutant receptors may reflect the unique activation mechanism of FLT3
. These results indicated that these Tyr-Phe substitutions impaired the kinase activity of mFLT3
Asp838Val itself.
Activation of downstream signal transduction molecules
Next, we examined the downstream signal transductions of Tyr-Phe mutants of mFLT3 Asp838Val . Total cell lysates of these transfected Ba/F3 cells were immunoblotted with anti-phospho-Erk1/2 antibody, anti-phospho-STAT3 antibody and anti-phospho-STAT5
antibody. The expressions of these downstream signal transduction molecules were confirmed by the immunoblotting with anti-Erk1/2 antibody, anti-STAT3 antibody and anti-STAT5 antibody (Figure 4a ).
FLT3
Asp838Val and Tyr796Phe mutant of mFLT3 Asp838Val showed constitutive activation of Erk1/2, STAT3 and STAT5, the levels of which were slightly weaker or comparable with that of the activation by interleukin-3 (IL-3). Tyr845Phe, Tyr892Phe and Tyr922Phe significantly impaired the activation of Erk1/2, STAT3 and STAT5, the levels of which were much weaker than that of the activation by IL-3. The expression of Pim-2, which is the target gene of STAT3/5, was also examined by real-time RT-PCR ( Figure 4b 
of two independent experiments
Critical tyrosine residues in FLT3 mutation J Ishiko et al . The suppressed expression of Pim-2 in these mutants was not induced by FLT3 ligand stimulation either. These results were consistent with the impaired activation of STAT3 and STAT5 in Tyr845Phe, Tyr892Phe and Tyr922Phe mutants of FLT3 Asp838Val .
Cell proliferation and cell survival
To examine the effects of Tyr-Phe substitutions on proliferative activity, the cell proliferation of transfected Ba/F3 cells was measured by 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay with various concentrations of FLT3 ligand or IL-3 ( Figure 5a ). The Ba/F3 cells expressing mFLT3
Asp838Val and Tyr796Phe of mFLT3 Asp838Val caused ligand-independent proliferation. The proliferation of the Ba/F3 cells expressing Tyr845Phe of mFLT3 Asp838Val was reduced by 60% compared to that of mFLT3
Asp838Val
, and the proliferations of the Ba/F3 cells expressing Tyr892Phe and Tyr922Phe of mFLT3 Asp838Val were completely abolished, whereas all of these transfected Ba/F3 cells proliferated in response to IL-3 at the similar level, that is to say, these clones had no intrinsic differences in proliferative activity. Different from Tyr892Phe and Tyr922Phe mutants, Tyr845Phe mutant retained the proliferative activity possibly due to the residual kinase activity, which was shown in Figure 3 . We also examined apoptosis of these transfected Ba/F3 cells after IL-3 depletion. In DNA histograms, the sub-G1 fractions corresponded to apoptotic cells (Figure 5b ). Only a small population of Ba/F3 cells expressing mFLT3
Asp838Val showed apoptosis in the absence of IL-3. In contrast, IL-3 deprivation led to a striking increase in apoptosis in the Ba/F3 cells expressing Tyr892Phe and Tyr922Phe of mFLT3 Asp838Val , indicating that Tyr892Phe and Tyr922Phe impaired the survival function of mFLT3
Asp838Val .
Effects of substitution of phenylalanine for tyrosine on WT and other constitutive active mutants of FLT3
To examine the effects of Tyr-Phe mutations on ligand-induced phosphorylation of wild-type mFLT3 (mFLT3 WT ), we constructed Tyr845Phe, Tyr892Phe and It has been reported that missense mutations in the kinase domain convert the tyrosine kinase into temperature-sensitive mutant (Mayer et al., 1986; Carlesso et al., 1994) . A temperature-sensitive mutant of v-Src has been created by two mutations; one is substitution of Val 461 for Met and the other is substitution of Pro 503 for Ser (Mayer et al., 1986) . A temperature-sensitive mutant of Bcr-Abl has been caused by two mutations, which are substitutions, Arg 457 to His and Tyr 469 to His of c-Abl (Carlesso et al., 1994 Critical tyrosine residues in FLT3 mutation J Ishiko et al signal transduction molecule, Erk1/2, also recovered at 331C compared to at 371C in these transfected Ba/F3 cells, as shown by the intensity of p-Erk in Figure 7a . We also examined the cell viability of these transfected Ba/F3 cells at 33 and 371C by trypan blue dye exclusion test (Figure 7b ). While the viability of Ba/F3 cells expressing mFLT3 Asp838Val was the same between at 33 and 371C, the decreased viability of Ba/F3 cells transfected with Tyr845Phe, Tyr892Phe and Tyr922Phe mutants of mFLT3
Asp838Val were improved to some extent by shifting the culture temperature from 37 to 331C. These results indicated that the Tyr-Phe mutants had the temperature-sensitive character, and suggested the possibility that the degradation of mFLT3
Asp838Val may be enhanced in Tyr-Phe mutants. To confirm this possibility, we performed the protein degradation assay of Tyr-Phe mutants. The transfected Ba/F3 cells were cultured at 371C with the inhibitor of protein synthesis, cycloheximide (CHX), and were lysed at indicated hours after treatment with CHX. The immunoprecipitates with anti-mFLT3 antibody from these lysates were subjected to immunoblotting with anti-mFLT3 antibody (Figure 7c ). We quantified both mature and immature bands of mFLT3 mutants by chemical image analyzer, and calculated the ratios of mFLT3 expression at the indicated times compared to mFLT3 expression without CHX in each mutants (mFLT3 expression at the indicated time/mFLT3 expression at time 0). The expressions of Tyr-Phe mutants of mFLT3 Asp838Val declined more rapidly than the expression of mFLT3
Asp838Val
. We also examined the intracellular and membrane expression of mFLT3 mutants by FACS analysis after permeabilization (Figure 7d ). This analysis confirmed that the expressions of Tyr-Phe mutants of mFLT3
Asp838Val after CHX treatment were significantly reduced compared to that of mFLT3 Asp838Val . These results indicated that the mutations of Tyr845Phe, Tyr892Phe and Tyr922Phe caused mFLT3
Asp838Val unstable and easy to degrade, which reflected the temperature-sensitive character.
Effects of chaperone proteins, Hsp90 and Cdc37, on the activation of Tyr-Phe mutants of mFLT3
The temperature-sensitive character suggested that these mutations caused the conformational change, which led to the impaired kinase activity and easy degradation. Since the conformation and the activity of various kinases are regulated by chaperone proteins such as Hsp90 and Cdc37, we examined whether the suppressed kinase activity of Tyr-Phe mutants of mFLT3 Asp838Val could be rescued by Hsp90 and Cdc37. We co-transfected chaperone proteins, Hsp90 and Cdc37, with mFLT3 mutants to Plat-E cells at 371C, and analysed the activation of mFLT3. The co-expression of Hsp90 and Cdc37 augmented the kinase activity of Tyr845Phe, Tyr892Phe and Tyr922Phe mutants about 1.30-1.64-fold as shown in fold increase (Figure 8a ). In this experiment, mFLT3 of Tyr845Phe and Tyr922Phe were phosphorylated even without co-expression of chaperones. We considered that this was due to the overexpression of these mutants. Hsp90 and Cdc37 were detected in FLT3 immunoprecipitates (Figure 8b ), which indicated that Hsp90 and Cdc37 could bind to and serve as chaperone proteins for FLT3 Asp838Val and Tyr-Phe mutants. These results suggested that two To investigate the effects of chaperone proteins on downstream signaling and cell function, we constructed Ba/F3 cell lines stably expressing Hsp90 and Cdc37, in addition to mFLT3 mutants. Stable expression of Hsp90 and Cdc37 showed the recovery of Erk1/2 activation and cell proliferation in the cell line expressing Tyr845Phe mutant (Figure 8c and d) . In contrast, Hsp90 and Cdc37 could not rescue the Erk activation and the proliferation substantially in Tyr892Phe and Tyr922Phe mutants, although the increase of proliferation was statistically significant. These results suggested that the effects of Hsp90 and Cdc37 were different between Tyr-Phe mutants, and the sufficient recovery of Tyr892Phe and Tyr922Phe mutants may require additional support by other chaperone proteins.
Discussion
We have previously shown that there are crucial cytoplasmic tyrosine residues regulating the activation of murine c-Kit TKD-mutant (KIT Asp814Val ) (Hashimoto et al., 2003) . The phenylalanine substitution of Tyr 719 in the kinase insert of KIT Asp814Val impaired not only the binding of p85 subunit of PI3-kinase but also the activation of the receptor itself, resulting in the complete inhibition of KIT Asp814Val -mediated growth (Hashimoto et al., 2003) . These results suggested that the constitutive activation of KIT Asp814Val depend on the specific tyrosine residues. With the advent of the similar approach, we have found that Tyr 845 , Tyr 892 and Tyr 922 critically regulate the activation of mFLT3 TKD-mutant. Although c-Kit and FLT3 have 22 cytoplasmic tyrosine residues and two-third of these tyrosine residues are conserved, the most critical tyrosine residues were different in both tyrosine kinases, which suggested the specific regulation of kinase activity in each RTK. We have confirmed the inhibition of mFLT3 Asp838Val activation by these three tyrosine residues in different cell lines and also in different transfection systems. Since we found that the phosphorylation of Tyr 592 , which is the autophosphorylated residue on receptor activation, was clearly reduced in these mutants, the impaired tyrosine phosphorylation of the receptor was not simply due to the loss of each tyrosine residue, but to the inhibition of the receptor activation. Tyr845Phe, Tyr892Phe and Tyr922Phe not only inhibited the several downstream signal transductions, Ras/MAP kinase, STAT3 and STA5 but also the ligand-independent proliferation and survival mediated by mFLT3
Asp838Val . Taken mutations inhibited the kinase activation of other mFLT3 mutations, corresponding to human FLT3 mutations such as ITD, Tyr835Phe and Ile836del, which have been detected in patients with AML. These results suggested that these tyrosine residues were also the common regulatory region of various active mutations of FLT3. Tyr 845 is the tyrosine residue located in the activation loop of mFLT3, and has been identified as the autophosphorylation site (Yu et al., 2003) . The tyrosine residues in the activation loop are conserved in all tyrosine kinase family, the phosphorylation of which has been shown to change the conformation of activation loop into active open form in the crystal structural analysis of FGFR1 and IRK (Mohammadi et al., 1996; Hubbard, 1997) . The crystal structure of human FLT3 indicated that the activation loop of FLT3 has similar configuration with that of IRK, and Tyr 842 of human FLT3, corresponding to Tyr 845 of mFLT3, adopted an orientation identical to its equivalent tyrosine of activation loop in IRK (Tyr 1142 ) (Griffith et al., 2004) . These reports suggested that the phosphorylation of Tyr 845 may regulate the activation of WT FLT3, and possess a similar role in the activation of TKD-mutant.
Concerning the significance of Tyr 892 and Tyr
922
, it has been reported that there are temperature-sensitive mutants of v-Src and Bcr-Abl, which has a mutation in the similar region. Tyr 892 of mFLT3 is located in the sequence of Gly-X-X-Pro-Tyr 892 -Pro, which is the conserved sequence among tyrosine kinase family. The corresponding sequence of v-Src is Gly-Arg-Val 461 -ProTyr-Pro, and the substitution of Met for Val 461 in this region together with another Pro503Ser mutation made v-Src into temperature-sensitive mutant (Mayer et al., 1986) . The temperature-sensitive mutant of Bcr-Abl is created by Tyr457His and Tyr469His mutations of c-Abl, the latter corresponding to Tyr 922 of mFLT3 (Carlesso et al., 1994) . Therefore, we addressed the temperature-sensitive character of Tyr-Phe mutants of mFLT3
Asp838Val . Tyr845Phe, Tyr892Phe and Tyr922Phe mutants showed the improvement in the receptor phosphorylation, MAP kinase activation and the survival at 331C compared to 371C, indicating temperaturesensitive character of these mutants. The half-life of these Tyr-Phe mutants was shorter than mFLT3 Asp838Val , which suggested that Tyr-Phe mutations affected the protein stability of the receptor. The temperaturesensitive character suggested that these Tyr-Phe mutations caused the conformational change of mFLT3 Asp838Val , which led to the impaired kinase activity and easy degradation. We suggested that lowering temperature could correct the unstable deformed structure of the Tyr-Phe mutants of mFLT3
Asp838Val , which resulted in more proper form with less degradation and sufficient kinase activity. However, lowering temperature itself may not be sufficient for the complete reforming of the distorted structure, which corresponded to the incomplete recovery of kinase activity and cell survival as shown in Figure 7a and b. In order to support this hypothesis that these mutations affected the steric conformation, we examined whether the suppressed kinase activity of Tyr-Phe mutants of mFLT3 Asp838Val could be rescued by Hsp90 and Cdc37. We have found that co-expression of chaperone proteins, Hsp90 and Cdc37, could partially improve the activation of the Tyr-Phe mutants of mFLT3 Asp838-Val under the condition of high expression of FLT3. This result suggested that Hsp90 and Cdc37 could correct the conformation of the mutant receptors, which resulted in the recovery of the kinase activity. This finding was consistent with our previous report that Hsp90 and Cdc37 could buffer the impaired activity at higher temperature of a temperature-sensitive mutant of constitutive active Hck (Scholz et al., 2001) . However, Hsp90 and Cdc37 could not effectively rescue the impaired activity of Tyr892Phe and Tyr922Phe in Ba/F3 cells, which suggested that other chaperone proteins may be necessary.
In conclusion, we have identified the critical tyrosine residues, which may be important to stabilize the active structure of FLT3 TKD-mutant. Although the crystal structure of FLT3 has been revealed, it has not been clear how the mutations of activation loop cause the structural change (Griffith et al., 2004) . Although Tyr 892 and Tyr 922 have not been identified as the autophosphorylation sites in FLT3
WT (Yu et al., 2003) , they could be phosphorylated aberrantly in FLT3 active mutants. It is also possible that these residues may be involved in the proper folding of FLT3 kinase domain without phosphorylation. It has been reported that the replacement of Tyr with Phe in IRK result in the change of basal kinase activity without tyrosine phosphorylation . More detailed structural analysis of these mutants may reveal how these tyrosine residues function in the stabilization of protein structure of FLT3, and may facilitate the development of small molecules inhibiting oncogenic FLT3.
Materials and methods

Construction of transgene
The constructs of mFLT3
Asp838Val was described previously (Fenski et al., 2000) . To construct various mutants of mFLT3
Asp838Val in which each cytoplasmic tyrosine residue was substituted by phenylalanine, we used QuikChanget SiteDirected Mutagenesis Kit (Stratagene). We made 22 primers for Tyr-Phe substitution and carried out site-directed mutagenesis on the expression vector pcDNA3 and pGD carrying mFLT3
Asp838Val cDNA. The mutation as well as the whole sequence was confirmed by DNA sequencing. We also made three other constitutive active mutants of mFLT3 by using QuikChanget. The one mutation was mFLT3-ITD, which had tandem insertion of Arg-Glu-Tyr-Glu-Asp-Lys between amino acids 602/603, similar with previously reported human FLT3-ITD (Spiekermann et al., 2003) . The other two mutations were mFLT3 Asp838Tyr and mFLT3
Ile839Del
, which respectively corresponded to human FLT3 Asp835Tyr and FLT3
Ile836del detected in patients with AML. For the expression of Cdc37 and Hsp90, we used pEF-BOS vectors, which contain human CDC37 and HSP90 (Scholz et al., 2000) .
Cell lines
The Plat-E cells, derived from human embryonic kidney cells, 293 T cells (Morita et al., 2000) , were maintained in Dulbecco's modification of Eagle's medium (Nacalai-Tesque Inc.) supplemented with 10% fetal bovine serum (FBS; EQUITEC-BIO Inc.). The Ba/F3 cells, murine IL3-dependent pro-B lymphoid cell line, were cultured in RPMI 1640 medium with L-glutamine (Nacalai-Tesque) and 10% FBS.
Transfection
The expression vector pcDNA3 (10 mg) was transiently transfected into Plat-E cells by the calcium-phosphate method.
On the next day, we confirmed the mFLT3 expression by staining with PE anti-mouse CD135 (Flk-2/FLT-3) antibody (BD Biosciences) and analysing by FACScan (Becton Dickinson). The cells were used for further analysis 2 days after transfection. For stable gene transfer to Ba/F3 cells, we performed the electroporation with expression vector pGD (20 mg), and selected neomycin-resistant cells by culturing with 1 mg/ml G418 sulfate (Sigma-Aldrich). To establish Ba/F3 cell line stably expressing Hsp90 and Cdc37, expression vector pEF-BOS (20 mg) and pMAM/BSD (1 mg, blasticidin-resistant gene) were transfected by electroporation, and selected with 10 mg/ml blasticidin S (Calbiochem). The expression of Cdc37 and Hsp90 was confirmed by Western blotting. For each construct, we selected more than three clones that had the sufficient expression, and the results are shown as the representative of experiments with these different clones.
Immunoprecipitation and Western blotting
After the depletion of serum and factors for 12 h, cells were treated with 200 ng/ml of FLT3 ligand (PeproTech Inc.) or 10 ng/ml of IL-3 (Kirin Brewery) at 371C for 10 min. Cells were washed twice with phosphate-buffered saline (PBS; NacalaiTesque), and lysed with lysis buffer as described previously (Ueda et al., 2002) . For immunoprecipitation, cell lysates were incubated with rabbit polyclonal antibody to mFLT3 (Santa Cruz Biotechnology) and Protein G Sepharose 4 FastFlow (Amersham Bioscience). The immunoprecipitates and total lysates were resuspended in sodium dodecyl sulfate (SDS) sample buffer, heated, separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and subjected for Western blotting as described before. We used the following antibodies. Antiphosphotyrosine antibody (P-Tyr-100), anti-phospho-FLT3 (Tyr 591 ) antibody, anti-phospho-Erk1/2 antibody, anti-Erk1/2 antibody, anti-phospho-STAT3 antibody, anti-STAT3 antibody, anti-phospho-STAT5 antibody and anti-STAT5 antibody were from Cell Signaling Technology. Anti-FLT3 antibody was from Upstate Biotechnology, and anti-Hsp90 and anti-Cdc37 antibodies were from Santa Cruz Biotechnology.
Apoptosis assay and cell viability assay
Apoptosis in transfected cells were analysed by cellular DNA content with propidium iodide staining. Briefly, 2 Â 10 5 cells were cultured without IL-3 for indicated times, and fixed with 70% ethanol. Subsequently, cells were stained with propidium iodide (100 mg/ml), NP-40 (0.01%), and RNase (10 mg/ml) for 10 min at 371C. Stained cells were subjected to FACS analysis. To estimate cell viability of transfected cells, we used trypan blue dye exclusion test. After incubation for 1 min with 0.4% trypan blue (Wako Pure Chemical Industries), we counted blue-stained and nonstained cells, corresponding to dead and viable cells, respectively.
RNA isolation and real-time PCR
Total RNA was isolated from Ba/F3 cells stably expressing mFLT3
Asp838Val mutants using TRIzol reagent (Invitrogen). A total of 1 mg of RNA was reverse transcribed using random primer and Moloney murine leukemia virus reverse transcriptase according to the manufacturer's protocol (Clontech). The quantification of mRNA levels was carried out with the use of real-time fluorescence detection method as described before (Muller et al., 2000; Mizuki et al., 2003) . Primers and probes were designed as described below: The expression level of Pim-2 was calculated using standard curves generated by the serial dilutions of cDNA from IL-3-stimulated Ba/F3 cells. All samples were independently analysed at least twice. The housekeeping gene GAPDH served as an additional control for the cDNA quality. The expression levels of Pim-2 were divided by the GAPDH expression levels, which was used as the relative Pim-2 expression.
MTT assay
To investigate cell proliferation, we used an MTT rapid colorimetric assay as described before (Ueda et al., 2002) . Briefly, 2 Â 10 4 transfected Ba/F3 cells were cultured in the indicated conditions for 72 h at 371C. MTT (Sigma-Aldrich) was incubated in each well for final 4 h of culture.
Quantification of protein expression and phosphorylation
The protein expression levels were quantified by analysing the intensity of each band using chemical image analyzer FluorChem (Alpha-Innotech Corp.). The phosphorylation rate was calculated by the ratio of the intensity of phosphorylated protein to that of total protein.
Protein degradation assay
Transfected Ba/F3 cells were cultured in RPMI 1640 supplemented with 10% FBS without IL-3 in the presence of 10 mg/ml cycloheximide (CHX; Sigma-Aldrich). After indicated hours, a total of 1.0 Â 10 7 cells were lysed, immunoprecipitated with anti-mFLT3 antibody and subjected to immunoblotting with anti-mFLT3 antibody as described above. In addition, the transfected Ba/F3 cells (1.0 Â 10 6 cells), which were treated with CHX for 8 h, were fixed and permeabilized by IntraPrept permeabilization reagents (Immunotech). Then, both intracellular and membrane mFLT3 were stained with rabbit anti-mFLT3 antibody, and subsequently with goat anti-rabbit IgG (H þ L) fluorescein-conjugated secondary antibody (Chemicon International). The expression amounts of mFLT3 were analysed by flow cytometry.
